Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead compound, Lucid-MS, toward a randomized, double-blind, placebo-controlled phase 2 trial in multiple sclerosis (MS) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA). The clearance marks a critical step for a therapy that could fundamentally change how MS is treated by targeting the underlying cause of the disease rather than merely managing symptoms.
Lucid-MS is a patented, first-in-class, non-covalent inhibitor of peptidyl arginine deiminase 2 (PAD2). Unlike current MS therapies that suppress the immune system, Lucid-MS is designed to directly prevent and reverse demyelination—the degradation of the protective myelin sheath around nerve fibers that drives MS progression. In preclinical models, the compound has demonstrated the ability to both prevent and reverse myelin degradation, suggesting a disease-modifying potential that could address a significant unmet need.
The FDA's acceptance of the IND application allows Quantum BioPharma to proceed with clinical testing in humans, a major milestone for any drug candidate. The planned phase 2 trial will evaluate the safety and efficacy of Lucid-MS in MS patients, with the goal of establishing proof-of-concept for this novel mechanism of action. If successful, Lucid-MS could offer a new therapeutic option for the millions of people worldwide living with MS, a chronic and often debilitating neurological condition.
Adding to the scientific momentum, Quantum BioPharma is collaborating with Massachusetts General Hospital and Harvard Medical School on research involving the [¹⁸F]3F4AP PET imaging tracer. This tracer is being evaluated as a method to visualize and measure demyelination in the brain, which could provide a powerful tool for diagnosing MS, monitoring disease progression, and assessing treatment response. The collaboration underscores the company's commitment to advancing both therapeutic and diagnostic approaches for demyelinating diseases.
The broader biopharmaceutical landscape has seen several recent developments in areas of high unmet medical need, as highlighted in a recent editorial. Novartis AG (NYSE: NVS) received FDA approval for Pluvicto® in combination with an androgen receptor pathway inhibitor for certain patients with metastatic hormone-sensitive prostate cancer. Merck & Co. Inc. (NYSE: MRK) had its supplemental Biologics License Application for ENFLONSIA™ accepted by the FDA to expand its indication for certain children at increased risk for severe respiratory syncytial virus disease. TG Therapeutics Inc. (NASDAQ: TGTX) initiated a phase 2 trial of BRIUMVI® in adults with treatment-resistant schizophrenia, and Bristol-Myers Squibb Company (NYSE: BMY) reported positive phase 2 results from the registrational QUINTESSENTIAL trial evaluating arlocabtagene autoleucel in heavily pretreated relapsed and refractory multiple myeloma. These examples illustrate the industry's drive to address conditions where current options are limited.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS. Quantum also invented UNBUZZD™ and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026, along with royalty payments of 7% of sales until total payments reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.
For investors, the FDA clearance and the upcoming phase 2 trial represent a potential value catalyst. The latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. To view the full press release, visit https://ibn.fm/lCey9.
